Q4 2024 Anika Therapeutics Inc Earnings Call Transcript
Key Points
- Anika Therapeutics Inc (ANIK) reported a 25% increase in commercial channel revenue for the fourth quarter and a 17% increase for the full year, driven by strong international OA pain management growth.
- The company achieved more than 40% sequential growth in its Integrity product for the third consecutive quarter, with over 1,000 surgeries performed globally since its launch.
- Anika Therapeutics Inc (ANIK) successfully divested Arthrosurface and Parcus Medical, allowing the company to focus on its core HA products and streamline operations.
- The company received MDR approval for Hyalofast and filed the second PMA module, with plans for a US launch by 2026, indicating significant regulatory progress.
- Anika Therapeutics Inc (ANIK) completed a $15 million initial share repurchase plan ahead of schedule, demonstrating strong cash management and commitment to shareholder value.
- Overall revenue for the year decreased by 1% compared to 2023, with OEM channel revenue declining by 8% due to lower US sales from J&J and competitive pricing pressures.
- Fourth quarter gross margin decreased by 13 points to 56%, with adjusted gross margin down 11 points due to one-time legacy program expenses and product mix.
- Operating expenses for the fourth quarter totaled $17.8 million, with research and development expenses increasing by 18% due to one-time FDA filing fees.
- Adjusted EBITDA from continuing operations decreased by 44% compared to 2023, primarily due to one-time legacy program expenses and higher research and development costs.
- The company anticipates a challenging year for its OEM channel in 2025, with expected revenue declines of 12% to 18% due to pricing pressures from J&J.
Good evening, Good morning, ladies and gentlemen, and welcome to Anika's fourth quarter and year-end earnings conference call following the presentation, we will conduct a question-and-answer session. (Operator Instructions) Also note that this call is being recorded on Wednesday, March 12, 2025.
I will now turn the call over to Matt Hall, Director, Corporate Development and Investor Relations. Please go ahead, sir.
Thank you, Sylvie. Good evening, and thank you for joining us for Anika's fourth quarter and year end 2024 conference call and webcast. I'm Matt Hall, Anika's Director of Corporate Development and Investor Relations.
Our earnings press release was issued earlier this afternoon and is available on our Investor Relations website located at www.anika.com as are the supplementary PowerPoint slides that will be used for the discussion today.
With me on the call today are Dr
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
